# Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

> **NCT00529087** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 460 (actual)

## Conditions studied

- Constipation

## Interventions

- **DRUG:** N-methylnaltrexone bromide (MOA-728)
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00529087
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 460 (ACTUAL)
- **Last updated:** 2019-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529087, "Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00529087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*